HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

AbbVie (ABBV) closed the most recent trading day at $195.00, moving +2.3% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered ...

This was the stock's third consecutive day of gains.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

Analysts have provided new insights into AbbVie and Esperion, two major players in the healthcare sector. AbbVie’s stock has ...